Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Abbvie humira patent cliff navigation success?Are statins used routinely in the treatment of cattle?Guselkumab brand name?Excipients list used in dexamethasone creams?Mobic injection patent oehringer ingelheim france?
See the DrugPatentWatch profile for ruxolitinib
Apotex’s ruxolitinib is used to treat two main disease areas:
Ruxolitinib (marketed by Apotex in applicable markets) is targeted at: - Myelofibrosis, including primary myelofibrosis - Post–polycythemia vera myelofibrosis - Post–essential thrombocythemia myelofibrosis [1]
Ruxolitinib is also targeted at: - Polycythemia vera in patients who are resistant to or intolerant of hydroxyurea [1]
When people search for “diseases targeted by ruxolitinib,” the indications most often include: - Myelofibrosis (as primary or post-PV/post-ET) - Polycythemia vera after hydroxyurea intolerance or resistance [1]
The underlying ruxolitinib indications are driven by the drug’s regulatory labeling (not just the manufacturer). Apotex’s ruxolitinib targets the same labeled disease categories listed above for ruxolitinib products [1].
[1] https://www.drugs.com/ (search “ruxolitinib indications myelofibrosis polycythemia vera”)
Other Questions About Ruxolitinib :